Cationic PAMAM Dendrimers Disrupt Key Platelet Functions

被引:111
作者
Jones, Clinton F. [1 ]
Campbell, Robert A. [2 ]
Franks, Zechariah [2 ]
Gibson, Christopher C. [2 ,4 ]
Thiagarajan, Giridhar [3 ,4 ]
Vieira-de-Abreu, Adriana [2 ,5 ]
Sukavaneshvar, Sivaprasad [6 ]
Mohammad, S. Fazal [6 ,7 ,8 ]
Li, Dean Y. [2 ,9 ,10 ]
Ghandehari, Hamidreza [1 ,3 ,4 ]
Weyrich, Andrew S. [2 ,11 ,12 ]
Brooks, Benjamin D. [1 ]
Grainger, David W. [1 ,3 ,4 ]
机构
[1] Univ Utah, Dept Pharmaceut & Pharmaceut Chem, Salt Lake City, UT 84112 USA
[2] Univ Utah, Sch Med, Program Mol Med, Salt Lake City, UT 84132 USA
[3] Univ Utah, Nano Inst Utah, Utah Ctr Nanomed, Salt Lake City, UT 84108 USA
[4] Univ Utah, Dept Bioengn, Salt Lake City, UT 84112 USA
[5] Fiocruz MS, Inst Oswaldo Cruz, Lab Imunofarmacol, BR-21045900 Rio De Janeiro, Brazil
[6] Thrombodyne Inc, Salt Lake City, UT 84103 USA
[7] Univ Utah, Dept Pathol, Salt Lake City, UT 84132 USA
[8] Univ Utah, Utah Artificial Heart Inst, Salt Lake City, UT 84112 USA
[9] Univ Utah, Div Cardiol, Dept Internal Med, Salt Lake City, UT 84132 USA
[10] Univ Utah, Dept Oncol Sci, Salt Lake City, UT 84132 USA
[11] Univ Utah, Div Pulm, Dept Internal Med, Salt Lake City, UT 84132 USA
[12] Univ Utah, Div Crit Care Med, Dept Internal Med, Salt Lake City, UT 84132 USA
关键词
nanotoxicity; PAMAM dendrimers; platelet activation; biocompatibility; thrombin generation; SUPPORTED LIPID-BILAYERS; RED-BLOOD-CELLS; POLY(AMIDOAMINE) DENDRIMERS; DRUG-DELIVERY; IN-VITRO; BIOMEDICAL APPLICATIONS; ANUCLEATE PLATELETS; DENDRITIC POLYMERS; HOLE FORMATION; FACTOR-VA;
D O I
10.1021/mp2006054
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Poly(amidoamine) (PAMAM) dendrimers have been proposed for a variety of biomedical applications and are increasingly studied as model nanomaterials for such use. The dendritic structure features both modular synthetic control of molecular size and shape and presentation of multiple equivalent terminal groups. These properties make PAMAM dendrimers highly functionalizable, versatile single-molecule nanoparticles with a high degree of consistency and low polydispersity. Recent nanotoxicological studies showed that intravenous administration of amine-terminated PAMAM dendrimers to mice was lethal, causing a disseminated intravascular coagulation-like condition. To elucidate the mechanisms underlying this coagulopathy, in vitro assessments of platelet functions in contact with PAMAM dendrimers were undertaken. This study demonstrates that cationic G7 PAMAM dendrimers activate platelets and dramatically alter their morphology. These changes to platelet morphology and activation state substantially altered platelet function, including increased aggregation and adherence to surfaces. Surprisingly, dendrimer exposure also attenuated platelet-dependent thrombin generation, indicating that not all platelet functions remained intact. These findings provide additional insight into PAMAM dendrimer effects on blood components and underscore the necessity for further research on the effects and mechanisms of PAMAM-specific and general nanoparticle toxicity in blood.
引用
收藏
页码:1599 / 1611
页数:13
相关论文
共 50 条
[21]   Molecular dynamics simulations of PAMAM dendrimer-induced pore formation in DPPC bilayers with a coarse-grained model [J].
Lee, Hwankyu ;
Larson, Ronald G. .
JOURNAL OF PHYSICAL CHEMISTRY B, 2006, 110 (37) :18204-18211
[22]   PAMAM Nanoparticles Promote Acute Lung Injury by Inducing Autophagic Cell Death through the Akt-TSC2-mTOR Signaling Pathway [J].
Li, Chenggang ;
Liu, Haolin ;
Sun, Yang ;
Wang, Hongliang ;
Guo, Feng ;
Rao, Shuan ;
Deng, Jiejie ;
Zhang, Yanli ;
Miao, Yufa ;
Guo, Chenying ;
Meng, Jie ;
Chen, Xiping ;
Li, Limin ;
Li, Dangsheng ;
Xu, Haiyan ;
Wang, Heng ;
Li, Bo ;
Jiang, Chengyu .
JOURNAL OF MOLECULAR CELL BIOLOGY, 2009, 1 (01) :37-45
[23]   Pharmacokinetics and biodistribution of nanoparticles [J].
Li, Shyh-Dar ;
Huang, Leaf .
MOLECULAR PHARMACEUTICS, 2008, 5 (04) :496-504
[24]   Dendrimers:: Relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo [J].
Malik, N ;
Wiwattanapatapee, R ;
Klopsch, R ;
Lorenz, K ;
Frey, H ;
Weener, JW ;
Meijer, EW ;
Paulus, W ;
Duncan, R .
JOURNAL OF CONTROLLED RELEASE, 2000, 65 (1-2) :133-148
[25]   Dendrimer-platinate: a novel approach to cancer chemotherapy [J].
Malik, N ;
Evagorou, EG ;
Duncan, R .
ANTI-CANCER DRUGS, 1999, 10 (08) :767-776
[26]   Deformability of poly(amidoamine) dendrimers [J].
Mecke, A ;
Lee, I ;
Baker, JR ;
Holl, MMB ;
Orr, BG .
EUROPEAN PHYSICAL JOURNAL E, 2004, 14 (01) :7-16
[27]   Structural modifications of DMPC vesicles upon interaction with poly(amidoamine) dendrimers studied by CW-electron paramagnetic resonance and electron spin-echo techniques [J].
Ottaviani, MF ;
Daddi, R ;
Brustolon, M ;
Turro, NJ ;
Tomalia, DA .
LANGMUIR, 1999, 15 (06) :1973-1980
[28]   Targeted drug delivery with dendrimers: Comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex [J].
Patri, AK ;
Kukowska-Latallo, JF ;
Baker, JR .
ADVANCED DRUG DELIVERY REVIEWS, 2005, 57 (15) :2203-2214
[29]   A polyamidoamine dendrimer-capped mesoporous silica nanosphere-based gene transfection reagent [J].
Radu, DR ;
Lai, CY ;
Jeftinija, K ;
Rowe, EW ;
Jeftinija, S ;
Lin, VSY .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2004, 126 (41) :13216-13217
[30]  
Roberts JC, 1996, J BIOMED MATER RES, V30, P53, DOI 10.1002/(SICI)1097-4636(199601)30:1<53::AID-JBM8>3.0.CO